January 15 - 18, 2019
Abstract submission deadline: Thursday, November 8
Advance registration deadline: Tuesday, December 4
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
AACR has designated this live activity for a maximum of 18.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, March 4. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the this website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Melanoma is a deadliest form of skin cancer and its incidence is on a rise at an alarming 3.1% per annum (1). Its incidence has more than tripled in the US over the past 35 years.
Novel approaches to treating metastatic melanoma include immunotherapies, such as anti-CTLA monoclonal antibodies (tremelimumab, Ipilimumab) (2) and anti-PD-1 antibodies (nivolumab, MK-3475) (7); targeted therapies such as the selective mutant BRAFV600E inhibitors (vemurafenib, dabrafenib) (3, 4, 5) and the c-KIT inhibitors (imatinib, dasatinib, nilotinib) (6,7); and combination therapies. Despite the success of various "targeted" inhibitors, therapeutic responses in melanoma patients are often short-lived due to rapidly acquired drug resistance. Immunotherapies, while having a more durable impact, are effective in <50% of treated patients. Therefore, understanding melanoma biology and potential mechanisms of innate and acquired drug resistance is extremely important for the development of improved therapeutic options.
With so many recent advances, melanoma research is at a critical point where it is extremely important for the field to have a continuous exchange of information. The proposed AACR melanoma conference will provide a forum to accelerate the pace of research by promoting dissemination of the latest research findings to basic scientists and clinical investigators, and by encouraging translational "cross-talk". Besides exchanging information, researchers can form new collaborations that can translate into more effective therapeutic modalities.
This conference will be useful to basic, translational and clinical scientists, as well as physicians/practicing oncologists (medical, surgical, radiation) and those engaged in the development and use of new therapeutics.
After participating in this CME activity, physicians should be able to:
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
This activity is supported by professional educational grants and will be disclosed at the activity.
Please contact the Office of CME at (215) 440-9300 or email@example.com.